Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075264 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
A Phase 2 study of HPV Infection and Vulvar Diseases, sponsored by Frantz Viral Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 5
- Study locations
NCT06075264: Recruiting Phase 2 study of HPV Infection and Vulvar Diseases, sponsored by Frantz Viral Therapeutics.
NCT06075264 is a Phase 2 study of HPV Infection and Vulvar Diseases that is actively recruiting participants, run by Frantz Viral Therapeutics. The registered enrollment target is 27 participants, below the 234-participant average among 13 other HPV Infection trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06075264, a Phase 2 study of HPV Infection and Vulvar Diseases, is actively recruiting participants, sponsored by Frantz Viral Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).
Primary Outcome
Number of participants who have complete histologic response following topical artesunate ointment
Conditions Studied
Interventions
- DRUG Artesunate ointment
- DRUG Placebo ointment
Study Locations (5)
Ohio
- Cleveland Clinic Fairview Hospital - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Hillcrest Hospital - Mayfield Heights
Florida
- Florida Gynecologic Oncology - Fort Myers
Indiana
- Ascension St. Vincent - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06075264 shows while recruiting
NCT06075264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 234-participant average among 13 other HPV Infection trials with a reported enrollment target (88% lower).
The record links to 10 conditions, with HPV Infection appearing as the primary indexed condition, and to 2 interventions - of which Artesunate ointment is the first listed.
NCT06075264 lists 5 locations in 3 states (Ohio, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT06075264 about?
NCT06075264 is a clinical study titled "Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)". This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).
What is the current status of trial NCT06075264?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2023-12-06. Estimated completion is 2027-12.
What conditions does trial NCT06075264 study?
This clinical trial studies the following conditions: HPV Infection, Vulvar Diseases, Pre-Cancerous Dysplasia, HPV Disease, Vulvar HSIL.
What interventions are being tested in trial NCT06075264?
The interventions under investigation include: Artesunate ointment (DRUG), Placebo ointment (DRUG).
Who is sponsoring clinical trial NCT06075264?
This trial is sponsored by Frantz Viral Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075264 being conducted?
This trial has 5 study locations across Florida, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06075264's enrollment target sits among peer trials
27 12th of 13 higher than 2 of 13 other HPV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
RECRUITING · Phase 2
-
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
ACTIVE NOT RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI